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Abstract: Gene-silencing miRNA and siRNA are emerging as attractive therapeutics with 
potential to suppress any genes, which could be especially useful in combination cancer therapy 
to overcome multidrug resistant (MDR) cancer. Nanomedicine aims to advance cancer treatment 
through functional nanocarriers that delivers one or more therapeutics to cancer tissue and cells 
with minimal off-target effects and suitable release kinetics and dosages. Although much effort 
has gone into developing circulating nanocarriers with targeting functionality for systemic 
administration, another alternative and straightforward approach is to utilize formulations to be 
administered directly to the site of action, such as pulmonary and intratumoral delivery. The 
combination of gene-silencing RNA with drugs in nanocarriers for localized delivery is emerging 
with promising results. 
In this review, the current progress and strategies for local co-administration of RNA and 
drug for synergistic effects and future potential in cancer treatment are presented and discussed. 
Key advances in RNA-drug anticancer synergy and localized delivery systems were combined 
with a review of the available literature on local co-administration of RNA and drug for cancer 
treatment. It is concluded that advanced delivery systems for local administration of gene-
silencing RNA and drug hold potential in treatment of cancer, depending on indication. In 
particular, there are promising developments using pulmonary delivery and intratumoral delivery 
in murine models, but further research should be conducted on other local administration 
strategies, designs that achieve effective intracellular delivery and maximize synergy and 
feasibility for clinical use.  
Keywords: Drug delivery system; Combinatory treatment; Tumor; Synergy; RNA; Therapeutic 
substance 
  
Introduction 
 Cancer is the collective name given to a range of diseases in which cells of the body start 
to divide uncontrollably and invade surrounding tissues. There are numerous cancer types, 
differing in the location in the body, the cell type they originated from and genotypic 
characteristics. The underlying genetics behind formation of cancer cells and their behavior is 
highly complex. Some cancer genes are rather specific for certain cancer types, while others are 
commonly found in a wide range of cancer types [1]. It has also been shown that due to branched 
evolution the genetic profile commonly differs between primary and metastatic tumors [2, 3] and 
even within individual tumors [3]. Further complexity is added by that epigenetics also plays an 
important role in cancer development and progression [4, 5], metastasis [6, 7] and response to 
drug treatment [8]. 
 Given the large number of different cancers, different cell behaviors due to genetic and 
epigenetic profiles and circumstances associated with location and stage of cancer, it is no 
surprise that different scenarios require different treatments. Common currently used cancer 
treatments are surgery, chemotherapy, radiation therapy, targeted therapy (acting mainly on 
cancer cells through selectivity for factors other than rapid cell division) and immunotherapy [9]. 
Although there has been much advancement in methodologies and available treatments, 
chemotherapy remains a main treatment, sometimes used alone, but often used before or after 
surgery, or in conjunction with radiation or other therapeutic substances [10]. Unfortunately, 
chemotherapy associated with the use of very toxic drugs at high concentration distributed 
through whole body is causing a range of side effects from action also on non-cancerous cells. 
Common ones are nausea and vomiting, diarrhoea, mucositis and myelosuppression [11]. 
 One approach to reduce off-target side effect is to maximize the localization of drug to 
tumors and cancer cells. Smart nanocarriers that selectively accumulate at tumors or are taken up 
preferentially by cancer cells have been extensively researched [12]. However, another intuitive 
means to reduce off-target effects and systemic toxicity is to administer drug locally at the tumor 
site [13]. Several strategies have been explored for localized cancer therapy including drug-
releasing implants, intratumoral injection [13-16] and pulmonary administration (inhalation) in 
the case of lung cancer [17, 18]. Although not widely used, intratumoral injection of drugs is 
employed in the clinic, while for lung cancer there have been clinical studies on pulmonary 
administration, as evident from searches in the ClinicalTrials.gov database, but the authors are 
not aware of any formally approved drugs/drug delivery systems for this specific purpose. 
 In chemotherapy and targeted therapies (which may be considered a subclass of 
chemotherapy) a major limitation for effective treatment is that tumors often develop multidrug 
resistance (MDR) [8, 19, 20], with recent indications that this is due to outgrowth of resistant 
subpopulations that initially were present at low frequencies, but that were favored under the 
selective pressure of the treatment [20, 21]. There is now substantial evidence that 
subpopulations of so called cancer stem cells (CSC) contribute to this MDR-development [20]. 
Thus, a contemporary research topic is to combine substances that suppress MDR with cytotoxic 
agents, so that also the MDR subpopulations of cells in tumors are killed [22-24]. 
One therapeutic substance that currently is heavily investigated for the purpose of MDR 
suppression in combination therapy is gene-silencing RNA, such as small interfering RNA 
(siRNA) and microRNA (miRNA) [25-28]. Although those RNAs could in theory silence any 
gene, there are several challenges before clinical realization, for example stability of the RNA in 
the body, limited uptake by cells and off-target effects [24, 25, 27, 29]. Nanoparticles currently 
receive much academic interest as carriers for co-delivery of siRNA and drug to overcome such 
issues, with promising results in model systems [23, 25, 26, 28, 30]. However, the translation of 
circulating nanoparticles with advanced designs from laboratory studies to clinical use has 
proven challenging. It seems that drug delivery systems focusing on maximization of the 
synergistic effect of co-delivered gene-silencing RNA and drug after local administration to 
tumors could have a more straight-forward translation to clinical use. 
In this review we explore and discuss the potential and challenges for using local-
administration drug delivery systems to maximize synergistic effect between gene-silencing 
RNA and anticancer drugs in cancer treatment. First a background is given on the use of 
nanoparticles to co-deliver gene-silencing RNA and drug to cells. Subsequently, a brief 
background is given on drug delivery systems for local administration. This is followed by a 
review and discussion of literature on local co-administration of RNA and drug in cancer 
treatment. Finally, an outlook is provided on expected future developments. 
 
Designing nanocarrier-mediated co-delivery of gene-silencing RNA and drugs  
There has been extensive research on nanocarrier-mediated delivery of drug [12] and 
gene-silencing RNA [27, 30] alone. However, co-delivery of gene-silencing RNA and drug to 
achieve enhanced efficacy against cancer cells is now emerging [31, 32]. In achieving synergy 
between drugs and RNA it is critical that they reach their target cells and molecules 
simultaneously, or at least within timeframes where their effects overlap and could act 
synergistically. This could be achieved by administering individual formulations of RNA and 
drug that reach their targets independently, but that are designed so that effects overlap. In 
theory, drug molecules could be free in solution or in nanocarriers, but RNA has exclusively 
been loaded into nanocarriers in clinical trials [33], likely due to stability, cell penetration issues 
and extended release requirements. Another appealing approach is to co-formulate the RNA and 
the drug into nanocarriers so they simultaneously reach and enter individual cells. Fig. 1 presents 
a schematic drawing of intracellular delivery of gene-silencing RNA and anticancer drugs co-
loaded in nanocarriers or simultaneously administered individually, with common target 
mechanisms for synergistic effect indicated. 
There are several recent achievements that highlights the potential of nanoparticle-
mediated co-delivery of RNA and drug in cancer treatment. For example, Xu et al. showed that 
self-assembled nanocarriers of biodegradable poly(lactide-coglycolide)-b-poly(ethyleneglycol) 
diblock copolymer and cationic lipid nanocarrier, co-delivering a prodrug of cisplatin and siRNA 
against the REV1 and REV3L genes involved in the error-prone translesion DNA synthesis 
pathway (a postreplication DNA repair mechanism), achieved greatly enhanced cytotoxicity 
against Lymph Node Carcinoma of the Prostate (LNCaP) [34]. Salzano et al. investigated self-
assembled nanocarriers of polyethyelene glycol (PEG)-phosphatidyl ethanolamine to co-delivery 
paclitaxel and anti-survivin siRNA via intravenous administration in a murine ovarian xenograft 
model. They reported much improved reduction of tumor volume and weight for co-delivered 
substances, although nanocarrier delivered anti-survivin siRNA alone also achieved substantially 
better effect than the paclitaxel-only formulations [35]. In another approach, doxorubicin was 
conjugated to PEI using pH sensitive crosslinkers and the conjugates were complexed with 
siRNA against BCL2 and survivin. For both the siRNAs the nanocarrier-mediated co-delivery 
with doxorubicin achieved little-to-no improvement in cytotoxicity against lung cancer cells in 
vitro compared to administrations with free doxorubicin, but improved efficacy was observed in 
vivo in murine lung cancer models after pulmonary administration [36, 37]. Saad et al. reported 
that co-delivery of siRNA against MDR1 and BCL2 genes with doxorubicin in cationic 
liposomes achieved greatly improved cytotoxicity against MDR breast and ovarian cancer cells 
compared to administrations using free doxorubicin or co-delivery in nanocarriers with only one 
of the siRNAs [38]. Functionalization of the nanocarrier with ligands for surfaces receptors on 
target cancer cells can increase the effectiveness of co-delivering nanocarrier systems. For 
example, Cao et al prepared folic acid-functionalized poly(ε-caprolactone)-PEI nanocarriers for 
doxorubicin and siRNA against BCL2 and reported enhanced apoptotic effect in vitro against 
hepatic cancer cells for the functionalized nanocarriers [39]. 
The above highlight different approaches, and phenomena for nanocarrier-mediated 
delivery of siRNA and drug to achieve synergistic effect and suppression of MDR. Importantly, 
in vitro cytotoxicity is not directly transferable to in vivo since accumulation and residence time 
at site of action are important factors. The results that combined siRNA against multiple targets 
achieved improved efficacy is important since, in contrast to conventional drugs, different 
siRNA will have similar physicochemical properties and can thus generally be co-loaded into a 
nanocarrier. The discussed studies represent a selection of the literature and the interested reader 
is encouraged to find more information, with suggestions being [28, 31, 32, 40-47]. As 
mentioned, a major focus of nanomedicine and nanocarriers has been intelligent nanoparticles 
that travel the circulatory system and selectively affect target cells. However, there have been 
recent advancements in the use of nanomaterials for local administration of therapeutic agents 
directly to the site of action, thus circumventing the considerable challenges in preparing 
nanocarriers that are stable and maintain their intelligent targeting in the highly complex 
environment of the body. Below, a background is given on drug delivery systems for local 
administration, followed by a review and discussion on their use in co-delivery of gene-silencing 
RNA and drugs in cancer treatment. 
 
Drug delivery systems for local administration: basic concepts  
Local administration of therapeutics is successfully trialed already and clinically applied 
in cancer treatment [48]. However, since the purpose of local administration often is to achieve 
therapeutic concentration at the target site, while reducing off-target effects by minimizing 
concentration elsewhere, it is beneficial to increase residence time of the drug at the 
administration site. This can be achieved through a carrier matrix that remains at the site of 
administration and releases therapeutic substances in a controlled manner. Examples of systems 
for local administration are injectable in situ gelling materials [49-51], beads [48], inhalable 
particles [36, 52, 53], nanocarriers that remain at the site of administrations [54-56], 
microneedles [57, 58], liquid crystalline phases [59], creams and ointments [60, 61] and metal 
drug releasing implants [62, 63]. 
To extend therapeutic duration from a single local administration, controlled release 
functionality is desired and to maintain the extended release and large payloads are needed. 
However, burst release of a fraction of the therapeutic substance(s) is commonly observed [64], 
which can lead to dangerously high concentrations at short times. Furthermore, release of 
hydrophilic therapeutic molecules is generally fast and may be completed in less than 24 h [65]. 
To minimize burst release nanocarriers and nanostructured depots have been used to encapsulate 
the therapeutic molecules so that extended release with desired release kinetics is achieved [65-
68]. The extended therapeutic duration also puts demand on protection of sensitive therapeutic 
molecules that are prone to degradation in the body, such as RNA. Again, nanoparticles and 
nanostructured materials can be used to protect the substances until released to their targets, as 
demonstrated for RNA [56, 59, 69, 70]. This protective effect can be achieved by denying 
enzymes, such as RNAase, access to the therapeutic molecules, by providing a suitable chemical 
environment, and by keeping the substances in a stable physicochemical state. A schematic of 
basic concepts of a local-administration delivery systems is shown in Fig. 2. 
 
Local administration of siRNA and drug  
Local administration of siRNA per definition circumvent the challenge of reaching the 
target site (although there may be biological barriers to overcome) and the focus can thus be on 
design of materials with suitable release profiles, excellent protection of siRNA and effective cell 
internalization and gene-silencing. This is a contemporary research topic with efforts both in 
localized delivery and design of receptor-targeting nanocarriers that enter cells and release the 
RNA in a designed fashion, with nanostructured/nanocomposite materials emerging [71].  
Local co-administration of gene-silencing RNA and drug is recently emerging and 
already at this early stage there are indications of excellent potential in cancer treatment. The 
previously mentioned self-assembling nanocarriers of biodegradable poly(lactide-coglycolide)-b-
poly(ethylene glycol) diblock copolymer and cationic lipid, carrying cisplatin prodrug and 
siRNA against REV1 and REV3L were investigated for antitumor effect after intratumoral 
administration in a LNCaP xenograft model. The authors reported that co-delivery of drug and 
siRNAs effectively suppressed tumor growth. Noteworthy, all mice that received the co-
delivered siRNAs and drug survived over the 50 days of the experiment. In contrast, for control 
groups administered saline solution, free cisplatin prodrug, cisplatin prodrug in nanocarriers, and 
siRNA in nanocarriers in combination with free cisplatin prodrug, all mice died over the time of 
the experiment [34]. The Oh’s group also investigated nanocarrier-mediated intratumoral 
delivery. They used cationic liposomes and solid lipid nanoparticles to co-deliver siRNA against 
MCL1 and a MEK inhibitor [46] or paclitaxel [47]. Both formulations were evaluated in a 
murine KB xenograft model and achieved much improved tumor suppression compared to 
controls. Lee et al prepared small (< 10 nm) complexes of Pluronics F-68, siRNA against BCL2 
and benzethonium chloride [72]. In a murine xenograft model of aggressive and resistant breast 
cancer they found that peritumoral administration of the complexes resulted in synergy between 
the siRNA and drug so that improved tumor inhibition was achieved. The effectiveness was 
likely due to that the small size allowed for penetration and distribution of the complexes in the 
tumor after the peritumoral administration. 
An attractive local administration route for lung cancer is inhalation (pulmonary 
delivery), as it potentially provides a non-invasive route directly to the tumor [17, 73]. There are 
recent promising results on nanocarrier-mediated co-delivery of siRNA and anticancer drug to 
battle lung cancer. Xu et al. prepared conjugates between doxorubicin and polyethyleneimine 
(PEI) using a pH sensitive liker. They complexed the conjugates with siRNA against BCL2 or 
survivin and evaluated antitumor effect in a mice B16F10 xenograft lung cancer model [36, 37]. 
Co-delivery with either of the siRNA improved tumor suppression compared to controls. 
Interestingly, after 24 h the in vitro cytotoxicity against cancer cells was lower for the co-
delivered formulation compared to free doxorubicin, while after 48 h the cytotoxicity was 
comparable. The delayed effect in cytotoxicity combined with the improved performance in vivo 
indicates that the controlled release of doxorubicin from the carriers limited cytotoxicity in vitro, 
but improved in vivo effect, likely due to sustained residence time in the lungs. The results 
highlight the discrepancy that may exist between in vitro and in vivo performance. Taratula et al., 
reported similarly promising results for pulmonary delivery of siRNA against BCL2 and MDR1 
with paclitaxel in lipid nanocarriers modified with luteinizing hormone-releasing hormone for 
targeting of receptors overexpressed by lung cancer cells [74]. The co-delivered siRNA and drug 
reduced the tumor volume towards zero over the 24 days of the experiment. The paclitaxel-
nanocarrier without siRNA also achieved some reduction of tumor volume, while for other 
controls tumor growth was observed. They further reported that the pulmonary administration 
mainly resulted in localization to lungs, while for intravenous administration the majority of the 
nanocarriers accumulated in the liver. Interestingly, they observed that for pulmonary delivery 
the targeting functionality corresponded with preferential localization to tumor tissue. In another 
study the authors prepared similarly targeted porous silica nanoparticles for co-delivery of the 
same siRNAs and drugs. Again they reported excellent localization to the lungs after pulmonary 
delivery and improved cytotoxicity in vitro of the co-delivered substances [75]. However, the 
tumor suppression remains to be tested in vivo.  
In an elegant and advanced design, Conde et al. prepared near-infrared (NIR) photo-
responsive hydrogel patches loaded with anti-KRAS siRNA-gold nanoparticles and avastin-gold 
nanorods for triple-therapy (siRNA, drug and heat) [76]. The patches were implanted peritumoral 
in a mice LoVo-6-Luc-1 colorectal xenograft model and excellent results were achieved. The 
triple-treatment achieved greatly reduced tumor volume and all animals survived the 145+ days 
of the experiment under the survival criteria. In contrast, for the various control treatments all 
animals died within 45 days under the survival criteria (see Fig. 3). In another study the authors 
prepared implantable hydrogels of polyamidoamine G5 dendrimers complexed with triple-
helixes of two miRNAs, one suppressing tumor RNA and one replacing down-regulated miRNA 
[77]. The di-miRNA hydrogels greatly outperformed hydrogels loaded with different anticancer 
drugs when implanted peritumoral in a triple-negative breast cancer mouse model. Although not 
a combination of gene-silencing RNA and drug, the study do highlight the potential of local 
administration of substances with different target mechanisms in treatment of cancer. 
An overview of formulations for local administration of co-delivered siRNA and drug is 
given in Table 1. 
 
Outlook and conclusions 
 Although the few available studies seem limited to intra/peritumoral and pulmonary 
administration, the excellent results suggest that localized co-delivery of gene-silencing RNA 
and drugs can improve cancer treatment through these routes. Related studies indicate that other 
local administration routes and more advanced formulations should also be possible. For 
example, topical delivery of siRNA alone has been investigated for skin cancer treatment with 
promising results [58] and topical co-administration of siRNA and drug has been shown to 
inhibit skin inflammation [78]. The recently reported tri-therapeutic nanostructured implantable 
hydrogel patch [76] presents an interesting concept with a macroscopic depot housing 
siRNA/drug-loaded nanocarriers that are released in a controlled manner. 
Nanoparticle/nanocarrier composites can be designed with the macroscopic matrix being 
insoluble and biodegradable [79], which could offer a means to further protect the loaded siRNA 
and drug from degradation until released in a controlled manner. It seems that advanced 
implantable devices for co-delivery could be useful in some indications, but the invasiveness of 
the procedure may be limiting. An attractive approach from a clinical perspective is injectable 
gels [51]. Micro- and nano-structured injectable gels have been shown to offer excellent control 
over release of substances [49, 66, 67, 80, 81] and enhance miRNA efficacy [82]. It was recently 
reported that an in situ-forming, microcapsule-containing biodegradable gel loaded with 
chemokine and dual siRNA/DNA attracted dendritic cells and silenced Interleukin-10 gene 
expressions [80] and an injectable gel containing siRNA polyplexes achieved antitumor effect 
for four weeks from a single administration in a murine model [83]. It is expected that advanced 
injectable nanostructured gels could be developed for improved cancer treatments through 
topical or intra/peritumoral co-delivery of siRNA and anticancer drugs. In addition, the excellent 
results to date on local co-administration of gene-silencing RNA and anticancer drugs have been 
performed without much optimization of the delivery systems, generally comparing the 
performance of the delivery system with various controls, but not varying the properties of the 
delivery system itself. Thus, there is both room and need for fundamental studies that focus on 
critical design parameters of individual systems, the results from which will enable improved 
antitumor efficiency and design of local administration systems for co-delivery of siRNA and 
drug in various cancers. 
To conclude, co-delivery of gene-silencing RNA and anticancer drugs through local 
administration is emerging and pre-clinical results are so far promising. Developments in 
advanced, often nanostructured, local delivery systems are expected, as are fundamental studies 
to determine critical design parameters. Although speculative, with advancement of the 
nanomedicine and nanomaterials fields co-delivery of RNA and drugs may become established 
in cancer treatment and it seems that local administration has great potential in selected 
indications. 
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Figure legends 
Fig. 1. Drawing of intracellular delivery of gene-silencing RNA and anticancer drug through co-
delivery in nanocarriers or simultaneous individual delivery, with common target mechanisms 
for synergistic effect indicated. Typically, the gene-silencing RNA is used, through the RNA 
interference pathways, to degrade target mRNA from genes that counteract the effects of 
anticancer drugs. Examples of suppressed mechanisms include; DNA repair, drug efflux, anti-
apoptosis and activities of cancer related kinases. Note that for individual delivery of anticancer 
drug, the drug could be loaded in a nanocarrier, but for clarity only the case with free drug is 
included in the drawing. (A color version of the figure is available in the online version of the 
article) 
 
Fig. 2. Schematic showing basic functionalities of a delivery system for local administration. The 
drug loaded material (depot) contains a high concentration of therapeutic substance that over 
time is released through diffusion and/or degradation of the depot, resulting in a locally high and 
systemically low concentration of the therapeutic. It is important that the therapeutic substance is 
stable in the depot until it is released, this can be achieved by (i) providing a suitable chemical 
environment and (ii) preventing enzymes from reaching the therapeutic substance. Note that the 
size of the depot may range from individual nanoparticles to macroscopic samples and that 
degradation of the therapeutic substance is not always an issue. (A color version of the figure is 
available in the online version of the article) 
 
Table 1. Formulations evaluated in vivo for co-delivery of siRNA and anticancer drugs. 
Formulation siRNA 
target(s) 
Drug Administration 
route  
Animal 
model 
Results summary Ref. 
Suspension of self-assembled 
nanocarriers of biodegradable 
poly(lactide-coglycolide)-b-
poly(ethylene glycol) diblock 
copolymer and cationic lipid. 
REV1/REV3L Cisplatin 
prodrug 
Intratumoral Murine 
prostate 
xenograft 
Chemosensitization of cancer cells 
to platinum treatment. Synergistic 
effects on repression of tumor 
growth. 
[34] 
Suspension of N',N''-
dioleylglutamide-based cationic 
liposomes. 
MCL1 MEK inhibitor 
PD0325901 
Intratumoral Murine KB 
xenograft 
Co-delivery reduced expression of 
Mcl1 and pERK1/2 
proteins and reduced tumor cell 
survival. Co-delivery also much 
improved inhibition of tumor growth.  
[46] 
Suspension of cationic 1,2-
Dioleoyl-sn-glycero-3-
ethylphosphocholine-based solid 
nanoparticles 
MCL1 Paclitaxel Intratumoral Murine KB 
xenograft 
Co-delivery achieved greatest effect 
in vitro and greatest inhibition of 
tumor growth. 
[47] 
Nano-sized hydrophobically 
associated multiple 
monocomplex of Pluronics F-68, 
benzethonium chloride and 
siRNA. 
BCL2 Benzethonium 
chloride 
Peritumoral Murine 
MDA-MB-
231 
xenograft 
Simple physical mixing resulted in 
complexes with size < 10 nm. 
Peritumoral administration achieved 
synergistically enhanced effect 
against aggressive and resistant 
triple-negative breast cancer model. 
[72] 
Suspension of Doxorubicin-cis-
aconitic anhydride-PEI 
conjugates complexed with 
siRNA. 
BCL2 Doxorubicin 
conjugate 
Pulmonary Murine 
B16F10 
xenograft 
Co-delivery achieved enhanced 
inhibition of tumor growth compared 
to controls. 
[36] 
Suspension of siRNA 
complexed to doxorubicin 
conjugated with PEI through 
hydrazine bond. 
BIRC5 
(Survivin) 
Doxorubicin 
conjugate 
Pulmonary Murine 
B16F10 
xenograft 
Co-delivery achieved improved 
antitumor efficacy with low level of 
side effects. 
[37] 
Nanostructured lipid 
nanocarriers dressed with PEG 
and modified synthetic analog of 
luteinizing hormone-releasing 
hormone as a targeting moiety. 
MRP1 and 
BCL2 
Paclitaxel or 
doxorubicin 
Pulmonary Murine 
A549 
xenograft 
Effectively co-delivered anticancer 
drugs and siRNA. Enhanced anti-
tumor effect and reduced 
accumulation in non-target organs 
compared to intravenous injection. 
[74] 
Table 1
Conjugates of siRNA-gold 
nanoparticles and drug-gold 
nanorods embedded in 
dextran/dendrimer hydrogels 
patch 
KRAS Avastin Peritumoral 
implantation 
Murine 
LoVo-6-
Luc-1 CRC 
xenograft 
The triple-combination therapy 
(siRNA/drug/heat) led to tumor 
regression and survival of all test 
animals over the 145+ days of the 
investigation. 
[76] 
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